Investigational Drug Information for Tideglusib
✉ Email this page to a colleague
What is the development status for investigational drug Tideglusib?
Tideglusib is an investigational drug.
There have been 9 clinical trials for Tideglusib.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 3rd 2021.
The most common disease conditions in clinical trials are Myotonic Dystrophy, Alzheimer Disease, and Cardiomyopathies. The leading clinical trial sponsors are AMO Pharma Limited, Noscira SA, and i3 Research.
There are seventeen US patents protecting this investigational drug and one hundred and ten international patents.
Summary for Tideglusib
| US Patents | 17 |
| International Patents | 110 |
| US Patent Applications | 125 |
| WIPO Patent Applications | 115 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 2 (2021-03-03) |
| Vendors | 58 |
Recent Clinical Trials for Tideglusib
| Title | Sponsor | Phase |
|---|---|---|
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | AMO Pharma | Phase 2 |
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | Canadian Institutes of Health Research (CIHR) | Phase 2 |
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | Canadian SADS | Phase 2 |
Clinical Trial Summary for Tideglusib
Top disease conditions for Tideglusib
Top clinical trial sponsors for Tideglusib
US Patents for Tideglusib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tideglusib | ⤷ Sign Up | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) | ⤷ Sign Up |
| Tideglusib | ⤷ Sign Up | Reprogramming fibroblasts into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (San Francisco, CA) | ⤷ Sign Up |
| Tideglusib | ⤷ Sign Up | Thermoreversible compositions for administration of therapeutic agents | Frequency Therapeutics, Inc. (Woburn, MA) | ⤷ Sign Up |
| Tideglusib | ⤷ Sign Up | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | ⤷ Sign Up | |
| Tideglusib | ⤷ Sign Up | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | ⤷ Sign Up |
| Tideglusib | ⤷ Sign Up | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) | ⤷ Sign Up |
| Tideglusib | ⤷ Sign Up | Method to direct differentiation of pluripotent stem cells into functional heart muscle | GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, UNIVERSITATSMEDIZIN (Gottingen, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tideglusib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tideglusib | Australia | AU2015274334 | 2034-06-12 | ⤷ Sign Up |
| Tideglusib | Australia | AU2021201667 | 2034-06-12 | ⤷ Sign Up |
| Tideglusib | Australia | AU2023200895 | 2034-06-12 | ⤷ Sign Up |
| Tideglusib | Canada | CA2950774 | 2034-06-12 | ⤷ Sign Up |
| Tideglusib | China | CN106794175 | 2034-06-12 | ⤷ Sign Up |
| Tideglusib | European Patent Office | EP3154544 | 2034-06-12 | ⤷ Sign Up |
| Tideglusib | Japan | JP2017523141 | 2034-06-12 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
